Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics

Abstract:
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of Bruce J. Seeley as Senior Vice President & General Manager, Diagnostics. In this role, Mr. Seeley will have responsibility for providing strategic direction and commercial leadership for NanoString's newly formed Diagnostics business, including the global launch of its genomic test for breast cancer based on the PAM50 gene signature following regulatory clearance.

NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics

Seattle, WA | Posted on May 29th, 2012

Mr. Seeley joins NanoString with more than 20 years of U.S. and global oncology-focused experience. Most recently, he was Executive Vice President, Commercial at Seattle Genetics, where he built and led the commercial organization and successfully launched the company's first product: ADCETRIS, a targeted therapy for lymphoma. Before joining Seattle Genetics in 2009 he worked for Genentech (a wholly owned member of the Roche Group), most recently as Senior Director, Marketing, HER2 Brands, where he led the launch of HERCEPTIN in adjuvant breast cancer. From 2000 to 2004, Mr. Seeley worked for Aventis Pharma in increasing roles of responsibility, including Senior Director of New Product Commercialization and Licensing, Global Marketing, Oncology. Previously, he held various marketing and sales positions at Rhone-Poulenc Rorer and Bristol-Myers Squibb.

Mr. Seeley commented: "I've dedicated my career to delivering high-impact products that improve the lives of cancer patients. It is clear that molecular diagnostics will continue to play an increasingly pivotal role in driving newer and more effective treatments for cancer. I'm looking forward to applying the experience I gained commercializing targeted therapeutics toward ushering in a new era of personalized medicine enabled by in vitro diagnostics based on NanoString's powerful nCounter® technology."

"With this appointment, we are formalizing our commitment to building two synergistic businesses based on our nCounter Analysis System," said Brad Gray, President and CEO of NanoString Technologies. "Our Life Sciences business has grown rapidly under Barney Saunders' commercial leadership, and will now benefit even more strongly from his increased focus. Bruce's skills and experience perfectly match our objective of commercializing diagnostics that inform major decisions in the treatment of cancer, beginning with our PAM50-based breast cancer assay."

NanoString recently initiated its second clinical validation study for the PAM50 breast cancer assay, which will evaluate samples from more than 1,000 patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG8). Positive results from NanoString's first clinical validation study were presented last December by the study's independent investigators at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The study, which included more than 1,000 samples from the TransATAC study of postmenopausal women with hormone receptor-positive early-stage breast cancer (ESBC), met all primary and secondary objectives.

The nCounter platform is currently available for Research Use Only. NanoString's PAM50-based breast cancer assay is not currently available for use in diagnostic procedures.

####

About NanoString Technologies, Inc.
NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.

The NanoString Technologies design logo, NanoString, NanoString Technologies and nCounter are registered trademarks of NanoString Technologies, Inc. All other trademarks are property of their respective owners.

For more information, please click here

Contacts:
For NanoString Technologies
Nicole Litchfield
415-793-6468

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Halas wins American Physical Society's Lilienfeld Prize: Rice University nanoscientist honored for pioneering research in plasmonics October 23rd, 2017

GTC Shanghai Highlights GF’s Momentum in China: Company shares details of technology roadmap and customer adoption in the world’s fastest-growing market for semiconductors October 23rd, 2017

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Nanomedicine

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting(R) 2017 October 23rd, 2017

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Announcements

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Researchers bring optical communication onto silicon chips: Ultrathin films of a semiconductor that emits and detects light can be stacked on top of silicon wafers October 23rd, 2017

Nanotube fiber antennas as capable as copper: Rice University researchers show their flexible fibers work well but weigh much less October 23rd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project